[1] | Emanuela, F., Grazia, M., Marco D., Paola, L.M., Giorgio, F. and Marco, B. (2012): Inflammation as a Link between Obesity and Metabolic Syndrome. Journal of Nutrition and Metabolism, 2012(ID): 476380-7. |
[2] | Lumeng, C.N. and Saltiel, A.R. (2011): Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121(6):2111–2117. |
[3] | Argo, C.K. and Caldwell, S.H. (2009): Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis., 13:511–531. |
[4] | Yao, J., Zhi, M., Gao, X., Hu, P., Li, C., and Yang, X. (2013): Effect and the probable mechanisms of silibinin in regulating insulin resistance in the liver of rats with non-alcoholic fatty liver. Braz. J. Med. Biol. Res., 46(3): 270–277. |
[5] | Barshop, N.J., Sirlin, C.B., Schwimmer, J.B. and Lavine, J.E. (2008): Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 28: 13-24. |
[6] | Arsenault, B.J., Beaumont, E.P., Després, J.P. and Larose, E. (2012): Mapping body fat distribution: a key step towards the identification of the vulnerable patient? Ann. Med., 44: 758-772. |
[7] | Mirza, M.S. (2011): Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterology Volume 2011, Article ID 592404, 11 pages |
[8] | Haluzik, M. and Haluzikova, D. (2006): The role of resistin in obesity-induced insulin resistance. Curr. Opin. Investig. Drugs, 7:306–311. |
[9] | Laurikkaa, A., Vuolteenahoa, K., Toikkanenb, V., Rinnebc, V., Leppänena, T., Tarkkab, M., Laurikkab, J. and Moilanen E. (2014): Adipocytokine resistin correlates with oxidative stress and myocardial injury in patients undergoing cardiac surgery. Eur. J. Cardiothorac. Surg., 46(4):729-36. |
[10] | 10. Rangwala, S.M., Rich, A.S., Rhoades, B., Shapiro, J.S., Obici, S., Rossetti, L. and Lazar, MA. (2004): Abnormal glucose homeostasis due to chronic hyperresistinemia. Diabetes, 53:1937–1941. |
[11] | Elsayed, E.Y., Mohamed, A. S., Abd Elal, H. and Hamed, E. (2010): Diagnostic Role Of Resistin In Non-alchoholic Fatty Liver Disease. Nature and Science, 8(4):64-68. |
[12] | Hida, K., Wada, J., Eguchi, J., Zhang, H., Baba, M., Seida, A., Hashimoto, I., Okada, T., Yasuhara, A., Nakatsuka, A., Shikata, K., Hourai, S., Futami, J., Watanabe, E., Matsuki, Y., Hiramatsu, R., Akagi, S., Makino, H. and. Kanwar, SY. (2005): Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci (USA), 102(30): 10610-10615. |
[13] | Seeger, J., Ziegelmeier, M., Bachmann, A., Lo ¨ssner, U., Kratzsch, J., Bluher, M., Stumvoll, M. and Fasshauer, M. (2008): Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. J. Clin. Endocrinol. Metab., 93: 247–251. |
[14] | Jian, W., Peng, W., Xiao, S., Li, H., Jin, J., Qin, L., Dong, Y. and Su, Q. (2014): Role of Serum Vaspin in Progression of Type 2 Diabetes: A 2-Year Cohort Study. PLoS ONE, 9(4): e94763. |
[15] | Kukla, M., Zwirska-Korczala, K., Hartleb, M., Waluga, M., Chwist, A., Kajor, M., Ciupinska-Kajor, M., Berdowska, A., Wozniak-Grygiel, E. and Buldak, R. (2010a): Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand. J. Gastroenterol., 45:235–242. |
[16] | Genc, H., Dogru, T., Tapan, S., Kara, M., Ercin, C.N., Aslan, F., Kantarcioglu, M., Karslioglu, Y., Sertoglu,, E., Erbil, M.K. and Bagci, S. (2011): Circulating vaspin and its relationship with insulin sensitivity, adiponectin, and liver histology in subjects with non-alcoholic steatohepatitis. Scand J Gastroenterol., 46(11):1355-61. |
[17] | Wang, Z. and Nakayama, T. (2010): Inflammation, a Link between Obesity and Cardiovascular Disease. Mediators of Inflamm. 535918: 1-17. |
[18] | Rourke, J.L., Muruganandan, S., Dranse, H.J., McMullen, N.M. and Sinal, C.J. (2014): Gpr1 is an active chemerin receptor influencing glucose homeostasis in obese mice. J Endocrinol., pii: JOE-14-0069. |
[19] | Tan, B.K., Chen, J., Farhatullah, S., Adya, R., Kaur, J, Heutling, D., Lewandowski, K.C., O'Hare, J.P, Lehnert, H. and Randeva, H.S. (2009): Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes, 58:1971–1977. |
[20] | Bauer, S., Wanninger, J., Schmidhofer, S., Weigert, J., Neumeier, M., Dorn, C., Hellerbrand, C., Zimara, N., Schäffler, A. and Aslanidis, C. (2011): Sterol regulatory element-binding protein2 (SREBP2) activation after excess triglyceride storage induces chemerin in hypertrophic adipocytes. Endocrinology, 152: 26-3 |
[21] | Aktas, B., Yilmaz, Y., Eren, F., Yonal, O., Kurt, R., Alahdab, O.Y., Celikel, A.C., Ozdogan, O., Imeryuz, N., Kalayci, C. and Avsar, E.(2011): Serum levels of vaspin, obestatin, and apelin-36 in patients with nonalcoholic fatty liver disease. Metabolism: clinical and experimental, 60(4):544-9. |
[22] | Svegliati-Baroni, G., Candelaresi, C., Saccomanno, S., Ferretti, G., Bachetti, T., Marzioni, M., De Minicis, S., Nobili, L., Salzano, R., Omenetti, A., Pacetti, D., Sigmund, S., Benedetti, A., and Casini, A. (2006): Gastrointestinal, Hepatobiliary and Pancreatic Pathology. A Model of Insulin Resistance and Nonalcoholic Steatohepatitis in Rats. The American Journal of Pathology, 169: 3. |
[23] | Novelli, E., Diniz, Y., Galhardi, C. Ebaid, G., Rodrigues, H., Mani, F., Fernandes, A., Cicogna, A. and Novelli Filho, J. (2007): Anthropometrical parameters and markers of obesity in rats Laboratory Animals Ltd. Laboratory Animals, 41: 111–119. |
[24] | Gerbaix, M., Metz, L., Ringot, E. and Courteix, D. (2010): Visceral fat mass determination in rodent: validation of dual energy X-ray absorptiometry and anthropometric techniques in fat and lean rats. Lipids Health Dis., 9:140. |
[25] | Steppan, C.M. and Lazar, M.A. (2002): Resistin and obesity-associated insulin resistance. TRENDS in Endocrinology & Metabolism, 13(1):18-23. |
[26] | Tietz, N.W., Cook, T., and McNiven, M.A. (1995): Clinical Guide to Laboratory Tests, W.B. Saunders, Co., Philadelphia, 509:12. |
[27] | Temple, R.C., Clark, P.M., and Hales, C.N. (1992). Measurement of insulin secretion in type 2 diabetes: problems and pitfalls. Diabetic Medicine, 9: 503-12. |
[28] | Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. and Turner, R.C. (1985). Homeostasis model assessment: insulin resistance and μ-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412-19. |
[29] | Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X. and Zhai, Q. (2007): SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B.Cell Metab.,6:307-319. |
[30] | Allain C., Poon L.S., Chan C.S., Richmond W. and Fu P.C. (1974): Enzymatic determination of total serum cholesterol. Clin. Chem., 20: 470-475. |
[31] | Naito, H.K. (1989): Triglycerides in clinical chemistry: theory, analysis and correlation. Second edition by Kaplan LA and Pesce AJ. (U.S.A.), P. 997. |
[32] | Warnick, G.R., Benderson, V. amd Albers, N. (1983): Selected methods. Clin. Chem., 10:91-99. |
[33] | Friedwald, W.T., Levy, R.I. and Fredrickson, D.S. (1972): Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 18:499-502. |
[34] | Tietz, N. (1998): Fundamentals of Chlinical Chemistry, W. B. Saunders, Philadelphia, PA. |
[35] | Rec, J.S. (1970): Estimation of serum ALT. J.Clin.Biochem. 8:658. |
[36] | Kimberly, M.M., Vesper, H.W., Caudill, S.P., Cooper, G.R., Rifai, N., Dati, F. and Myers GL. (2003): Standardization of immunoassay for measurement of high-sensitivity C reactive protein phase 1: Evaluation of secondary reference materials. Clin Chem., 49:611–616. |
[37] | Martin, P. (1981): A guide to laboratory animal technology, 2nd ed. Willim Uheine, medical box limited, London. P71. |
[38] | Quick, A.J. (1966): Hemorrhage disease and thrombosis. 9 ed. Lea and Febiger, Philadelphia. P209. |
[39] | Arkin C. (1996): one stage PT and APTT. Approved Guide line vol. 16 no: 3 NCCLS. |
[40] | Ansell, J.E. (1992): Impression of prothrombin times monitoring of oral anticoagulants. Am. J. Clin. Path., 98:237-239. |
[41] | Cooper J. and Douglas A. (1991): Fibrinogen level as a Predictor of mortality in survivers of myocardial infarction. Fibrinolysis, 5:105-108. |
[42] | Declerck P.J., Mombaerts P., Holvoet P., DeMol M., Collen D. (1987): Fibrinolytic response and fibrin fragment D-dimers in patients with deep venous thrombosis. Thromb. Haemost., 58:1024-1029. |
[43] | Altunkaynak, Z. (2005): Effects of high fat diet induced obesity on female rat livers (A histochemical study). Eur. J. Gen. Med., 2(3):100-109. |
[44] | Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y-C., Torbenson, M.S., Unalp-Arida, A.,Yeh, M., McCullough, A.J. and Sanyal, A. J. (2005): Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology; 41: 1313-1321. |
[45] | Zhao, C.Y., Jiang, L.L., Li, L., Deng, Z.J., Liang, B.L., Li, J.M. (2004): Peroxisome proliferator activated receptor-gamma in pathogenesis of experimental fatty liver disease. World J. Gastroenterol, 10:1329–1332. |
[46] | Timpson, N.J., Lawlor, D.A., Harbord, R.M., Gaunt, T.R., Day, I.N., Palmer, L.J., Hattersley, A.T., Ebrahim, S., Lowe, G.D., Rumley, A. and Smith, D.G. (2005): C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet, 366:1954–9. |
[47] | You-min, W., Wen-ping, W., Li-ping, W., Qi-huan, L. and Xiao-hui, Z. (2010): Calorie control increased vaspin levels of serum and periepididymal adipose tissue in diet-induced obese rats in association with serum free fatty acid and tumor necrosis factor alpha Chin Med J., 123(7): 936-941 |
[48] | Sjoholm, A. and Nystrom, T. (2006): Inflammation and the etiology of type 2 diabetes. Diab. Metabol. Res. and Rev., 22: 4–10. |
[49] | Eisinger, K., Liebisch, G., Schmitz, G., Aslanidis, C., Krautbauer, A. and Buechler, C. (2014): Lipidomic Analysis of Serum from High Fat Diet Induced Obese Mice. Int. J. Mol. Sci. 15(2): 2991–3002. |
[50] | Zhang, X., Yang, J., Guo, Y., Ye, H., Yu, C., Xu, C., Xu, L., Wu, S., Sun, W., Wei, H., Gao, X., Zhu, Y., Qian, X., Jiang, Y., Li, Y. and He, F. (2010): Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl–Coenzyme A Hydratase Down-Regulation Exacerbates Hepatic Steatosis. Hepatology, 51(4): 1190-1199. |
[51] | Bugianesi, E., McCullough, A.J. and Marchesini, G. (2005): Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology, 42: 987–1000. |
[52] | Postic, C. and Girard, J. (2008): Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest., 118: 829–38. |
[53] | Lewis, G.F., Carpentier, A., Adeli, K. and Giacca, A. (2002): Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev., 23: 201–29. |
[54] | Day, C. P. (2002): Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut, 50(5): 585–588. |
[55] | Roberts, C.K, Vaziri, N.D., Liang, K.H., Barnard, R.J. (2001): Re-Versibility Of chronic experimental syndrome x by diet modification. Hypertension; 37: 1323-1328. |
[56] | Bieghs, V., Van Gorp, P.J., Wouters, K., Hendrikx, T., Gijbels, M.J., van Bilsen, M., Bakker, J., Binder, C.J., Lütjohann, D., Staels, B., Hofker, M.H. and Shiri-Sverdlov, R.(2012): LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS One, 7: e30668. |
[57] | Hui, J.M., Hodge, A., Farrell, G.C., Kench, J.G., Kriketos, A. and George, J. (2004): Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology, 40: 46–54. |
[58] | Stroubini, Th., Perelas, A., Liapi, C., Perrea, D., Dontas, I., Tzavara, Ch. and Galanopoulou P. (2009): Serum adiponectin and resistin in rats under three isocaloric diets: The effect of sibutramine. Cytokine, 46:171-175 |
[59] | Azuma, K., Katsukawa, F., Oguchi, S., Murata, M., Yamazaki, H., Shimada, A. and Saruta, T. (2003): Correlation between serum resistin level and adiposity in obese individuals. Obes. Res., 11(8): 997-1001. |
[60] | Silha, J.V., Krsek, M., Skrha, J.V., Sucharda, P., Nyomba, B.L., Murphy, L.J. (2003): Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlation with insulin resistance. Eur. J. Endocrinol. 149(4):331-5. |
[61] | de Luis, D.A., Sagrado, M. G., Conde, R., Aller, R., Izaola, O., Perez, Castrillon, J.L. and Duenõas, A. (2009): Relation of resistin levels with cardiovascular risk factors and insulin resistance in non-diabetes obese patients. Diab. Res. Clin. Pract., 84:174-178 |
[62] | Uslu, S., Kebapçi, N., Kara, M. and Bal, C. (2012): Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Experimental and therapeutic medicine, 4: 113-120. |
[63] | Vielma, A.S., Klein, L.R., Levingston, A.C. and Youg, R.I.M. (2014): Skewing of immune cell cytokine production by mediators from adipocytes and endothelial cells. Adipocyte, 3(2): 126–131. |
[64] | Zhou, L., Sell, H., Eckardt, K., Yang, Z. and Eckel, J. (2007): Conditioned medium obtained from in vitro differentiated adipocytes and resistin induce insulin resistance in human hepatocytes. FEBS Lett. 581:4303–4308. |
[65] | Baranova, A., Gowder, S.J., Schlauch, K., Elariny, H., Collantes, R., Afendy, A., Ong, J.P., Goodman, Z., Chandhoke, V. and Younossi, Z.M. (2006): Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes. Surg., 16:1118–1125. |
[66] | Pagano, C., Pilon, C., Olivieri, M., Mason, P., Fabris, R., Serra, R., Milan, G., Rossato, M., Federspil, G. and Vettor, R. (2006): Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab., 91:3165-3170. |
[67] | Al-Harithy RN and Al-Ghamdi S.(2005): Serum resistin, adiposity and insulin resistance in Saudi women with type 2 diabetes mellitus. Ann Saudi Med. 25(4):283-7. |
[68] | Melone, M., Wilsie, L., Palyha, O., Strack, A. and Rashid, S. (2012): Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J. Am. Coll. Cardiol., 59: 1697–1705. |
[69] | Baranova, A., Phuong, T., Tran, T., Afendy, A., Wang, L., Shamsaddini, A., Mehta, R., Chandhoke, V., Birerdinc, A., and Younossi, Z. M. (2013): Molecular signature of adipose tissue in patients with both Non-Alcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovarian Syndrome (PCOS). J. Trans. Med., 11: 133. |
[70] | Shen, C., Zhao, C-Y., Wang, W., Wang, Y-D., Sun, H., Cao, W., Yu W-Y., Zhang,L., Ji, R., Li, M. and Gao, J. (2014): The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. M.C. Gastroenterology, 14:39. |
[71] | Gambino, R., Bo, S., Musso, G, Uberti, B., Alemanno, N., Ghione, F., Guidi, S., Tiozzo, E., Chiusano, V., Gentile, L., Durazzo, M., Pagano, G. and Cassader, M. (2007): Microsomal triglyceride transfer protein 493-T variant is associated with resistin levels and C-reactive protein. Clin Biochem., 40 (16-17): 1219-24. |
[72] | Beier, J.I., Guo, L., von Montfort, C., Kaiser, J.P., Joshi-Barve, S., and Arteel, G.E. (2008): New Role of Resistin in Lipopolysaccharide-Induced Liver Damage in Mice. J. Pharmacol. Exp. Ther., 325(3): 801–808. |
[73] | Cho, Y.K., Lee, W.Y., Oh, S.Y., Park, J.H., Kim, H.J. and Park, D.I. (2007): .Factors affecting the serum levels of adipokines in Korean male patients with nonalcoholic fatty liver disease. Hepatogastroenterology, 54(77):1512-6. |
[74] | Fang-Fang, G., Ge-li, L., Rong-Xiu, Z., Li-Hong, J. and Peng-Li, B. (2013): correlation between vaspin concentration and insulin sensitivity in visceral adipose tissue of young obese rats. Chin. J.Con temp. Pediatr., 15(1): 71-74. |
[75] | Abdel-lateif, D. and El-Shaer, S. (2012): Association between changes in serum vaspin concentrations and changes of anthropometric and metabolic variables in obese subjects after weight reduction. J.Am. Sci., 8(4): 606-611. |
[76] | Saalbach, A., Vester, K., Rall, K., Tremel, J., Anderegg, U., Beck-Sickinger, A. G., Blüher, M. (2012). Vaspin--a link of obesity and psoriasis? Experimental dermatology, 21(4): 309–12. |
[77] | Goktas, Z., Owens, S., Boylan, M., Syn, D., Shen, C., Reed, D., San, Francisco, S, and Wang, S. (2013): Associations between Tissue Visfatin/Nicotinamide,Phosphoribosyltransferase (Nampt), Retinol Binding Protein-4, and Vaspin Concentrations and Insulin Resistance in Morbidly Obese Subjects. Mediators Inflamm., 2013: 861496. |
[78] | Atya, H. B., Hassan, Z. A., Amin, A. I., and Ali, S. A. E. (2013). Vaspin concentration in obesity , impaired glucose tolerance and Type 2 diabetes in Egypt. Adv. Res. Biol. Sci., 1(2): 6–13. |
[79] | Suleymanoglu, S., Tascilar, E., Pirgon, O., Tapan, S. and Meral, C. (2009): Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res. Clin. Pract., 84: 325–328. |
[80] | Inoue, J., Wada, J., Teshigawara, S., Hida, K., Nakatsuka, A., Takatori, Y., and Kojo, S. (2012). The serum vaspin levels are reduced in Japanese chronic hemodialysis patients. BMC nephrology, 13, 163-8. |
[81] | Giomisi, A., Kourtis, A., Toulis, K. a, Anastasilakis, A. D., Makedou, K. G., Mouzaki, M., and Gerou, S. (2011). Serum vaspin levels in normal pregnancy in comparison with non-pregnant women. Eur. J. Endocrinol., 164(4): 579–83. |
[82] | Ben-Dong, F., Hideyuki, Y., Muneyoshi, O. and Yukio, H. (2009): Vaspin cannot inhibit TNF-alpha-induced inflammation of human umbilical vein endothelial cells. J. Vet. Med. Sci., 71(9):1201-7. |
[83] | Gabriel, A., Kukla, M. and Ziolkowski, A. (2008): Histopathological features and current scoring systems for semiquantitative assessment of nonalcoholic fatty liver disease. Exp. Clin. Hep., 4: 48-54. |
[84] | Gulcelik, N. E., Karakaya, J., Gedik, A., Usman, A. and Gurlek, A. (2009): Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur. J. Endocrinol., 160(1): 65–70. |
[85] | Parlee, S.D., Ernst, M.C., Muruganandan, S., Sinal, C. and Goralski, J. (2010): Serum chemerin levels vary with time of day and are modified by obesity and tumour nescrosis-α. Endocrinology, 151: 2590-2602. |
[86] | Weigert, J., Neumeier, M., Wanninger, J., Filarsky, M., Bauer, S., Wiest, R., Farkas, S., Scherer, M.N., Schäffler, A., Aslanidis, C., Schölmerich, J. and Buechler, C. (2010): Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin. Endocrinol. (Oxf)., 72: 342–348. |
[87] | Sell, H., Laurencikiene, J., Taube, A., Eckardt, K., Cramer, A., Horrighs, A., Arner, P. and Eckel, J. (2009): Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes, 58: 2731-2740. |
[88] | Zabel, B.A., Kwitniewski, M., Banas, M., Zabieglo, K., Murzyn, K. and Cichy, J. (2014): Chemerin regulation and role in host defense. Am. J. Clin. Exp. Immunol., 3(1):1-19. |
[89] | Deng, Y., Wang, H., Lu, Y., Liu, S., Zhang, Q., Huang, J., Zhu, R., Yang, J., Zhang, R., Zhang, D., Shen, W., Ning, G. and Yang, Y. (2013): Identification of Chemerin as a Novel FXR Target Gene Down-Regulated in the Progression of Nonalcoholic Steatohepatitis. Endocrinology, 154(5): 1794-1801. |
[90] | Bozaoglu, K., Bolton, K., McMillan, J., Zimmet, P., Jowett, J., Collier, G., Walder, K. and Segal, D. (2007): Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology, 148 (10): 4687-94. |
[91] | Kukla, M., Zwirska-Korczala, K., Gabriel, A., Walga, M., Warakomska, I., Szczygiel, B., Berdowska, A., Mazur, W., Wozniak-Grygiel, E. and Kryczka, W. (2010b): Chemerin, vaspin and insulin resistance in chronic hepatitis C. J. Viral. Hepat., 17: 661-667. |
[92] | Elks, C. M. and Francis, J. (2010): Central adiposity, systemic inflammation, and the metabolic syndrome. Curr. Hypertens. Rep., 12: 99–104. |
[93] | Rius, B., López-Vicario, C., González-Périz, A., Morán- Salvador, E., García-Alonso, V., Clària, J. and Titos, E. (2012): Resolution of inflammation in obesity-induced liver disease. Frontiers in Immunology, Inflammation, 3: 257. |
[94] | Jung, H.S., Park, K.H., Cho, Y.M., Chung, S.S., Cho, H.J., Cho, S.Y., Kim, S.J., Kim, S.Y., Lee,, H.K. and Park, K.S. (2006): Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc. Res., 69:76-85. |
[95] | Reilly, M.P., Lehrke, M., Wolfe, M.L., Rohatgi, A., Lazar, M.A. and Rader, DJ. (2005): Resistin is an inflammatory marker of atherosclerosis in humans. Circulation, 111: 932- 939. |
[96] | Mojiminiyi, O.A. and Abdella, N.A. (2007): Associations of resistin with inflammation and insulin resistance in patients with type 2 diabetes mellitus. Scand. J. Clin. Lab. Invest., 67: 215-225. |
[97] | de Luis, D.A., Sagrado, M.G., Conde, R., Aller, R., Izaola, O., de la Fuente, B., Castrillón, J.L. and Romero, E. (2010): Relation of resistin levels with cardiovascular risk factors, insulin resistance and inflammation in naïve diabetes obese patients. Diabetes Res. Clin. Pract., 89: 110-114. |
[98] | Barnea, G., Strapps, W., Herrada, G., Berman, Y., Ong,, J., Kloss, B., Axel, R. and Lee, K.J. (2008): The genetic design of signaling cascades to record receptor activation. Proc. Natl. Acad. Sci. U. S. A., 105: 64-69. |
[99] | Lehrke, M., Becker, A., Greif, M., Stark, R., Laubender, R.P., von Ziegler, F., Lebherz, C., Tittus, J., Reiser, M., Becker, C., Goke, B., Leber, A.W., Parhofer, K.G. and Broedl, U.C. (2009): Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur. J. Endocrinol., 161: 339–344. |
[100] | Tripodi, A., Anna, L., Fracanzani, L.A., Primignani, M., Chantarangkul, V., Clerici, M., Mannucci, M.P., Peyvandi, F., Bertelli, C., Valenti, L. and Fargion, S. (2014): Procoagulant imbalance in patients with non-alcoholic fatty liver disease. Journal of Hepatology, 61(1): 148–154. |
[101] | Schäfer, K. and Konstantinides, S. (2011): Adipokines and thrombosis. Clin Exp. Pharmacol. Physiol., 38: 864-871. |
[102] | Anfossi, G., Russo, I. and Trovati, M. (2009): Platelet dysfunction in central obesity. Nutr. Metab. Cardiovasc. Dis., 19: 440-449. |
[103] | Russo, I., Del Mese, P. and Doronzo, G. (2007): Platelet resistance to the antiaggregatorycyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. Clin. Chem., 53: 1053-1060. |
[104] | Korporaal, S.J. and Akkerman, J.W. (2006): Platelet activation by low density lipoprotein and high density lipoprotein. Pathophysiol. Haemost. Thromb., 35: 270-280. |
[105] | Morange, P-E. and Alessi, M-C. (2013): Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology. Thromb. Haemost., 110: 669–680. |
[106] | Meli, R., Mattace Raso, G., Irace, C., Simeoli, R., Di Pascale, A.., Paciello, O., Pagano, T.B., Calignano, A., mail, A.C. and Santamaria, R. (2013): High Fat Diet Induces Liver Steatosis and Early Dysregulation of Iron Metabolism in Rats. PLoS ONE., 8(6): e66570. |
[107] | Konstantinides, S., Schafer, K. and Loskutoff, D.J. (2001): The prothrombotic effects of leptin possible implications for the risk of cardiovascular disease in obesity. Ann. N.Y. Acad. Sci., 947: 134-141. |
[108] | Rafail, S., Ritis, K., Schaefer, K., Kourtzelis, I., Speletas, M., Doumas, M., Giaglis, S., Kambas, K., Konstantinide, S. and Kartalis, G. (2008): Leptin induces the expression of functional tissue factor in human neutrophils and peripheral blood mononuclear cells through JAK2-dependent mechanisms and TNFα involvement. Thrombo. Res., 122: 366–375. |
[109] | Grant, P.J. (2007): Diabetes mellitus as a prothrombotic condition. J. Intern. Med., 262: 157-172. |
[110] | Mineo, C., Deguchi, H., Griffin, J.H. and Shaul, P.W. (2006): Endothelial and antithrombotic actions of HDL. Circ. Res., 98: 1352-1364 |
[111] | Arteaga, R.B., Chirinos, J.A., Soriano, A.O, Horstman, L., Jimenez, J.J., Mendez, A., Ferreira, A., de Marchena, E. and Ahn, Y.S. (2006): Endothelial microparticles and platelet and leukocyte activation in patients with the metabolic syndrome. Am. J. Cardiol., 98: 70-74. |
[112] | Tripodi, A., Primignani, M., Chantarangkul, V., DellÕEra, A., Clerici, M., de Franchis, R., Colombo, M. and Mannucci, P.M. (2009): An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. Gas-Troenterology, 137: 2105–11. |
[113] | Tripodi, A., Primignani, M., Lemma, L., Chantarangku, V., DellÕEra, A., Iannuzzi, F., Aghemo, A., Mannucci, P.M. (2010): Detection of the imbalance of pro- vs. anti-coagulant factors in cirrhosis by a simple laboratory method. Hepatology, 52: 249–55. |
[114] | Remkova, A. (2006): Diagnostic approach to hypercoagulable state. Bratisl Lek Listy, 107(8): 292-295. |
[115] | Levi, M., Toh, C.H., Thachil, J. and Watson, H.G. (2009): Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol; 145:24 |
[116] | Hodge, A. and Crispin, P. (2010): Coagulopathy in liver disease: The whole is greater than the sum of its parts. J. Gastroenterol. Hepatol., 25: 116-121. |
[117] | Tripodi, A., Mannucci, P.M (2011): the Coagulopathy of Chronic Liver Disease. N. Engl. Med., 365: 147-56. |
[118] | Hoseen, M.I., Hassan, M.I., Abd-Alaleem, D.I. and Faragallah, E.M. (2010): Serum resistin levels and haemostatic changes in experimentally induced diabetic and high fat fed rats. Journal of American Science, 6(8):557-567. |
[119] | Bobbert, P., Eisenreich, A., Weithäuser, A., Schultheiss, H.P. and Rauch, U. (2011): Leptin and resistin induce increased procoagulability in diabetes mellitus. Cytokine, 56:332–337. |
[120] | Gentile, M., Vecchione, C., Marino, G., Aretini, A., Pardo, A., Antenucci, G., Maffei, A., Cifelli, G., Louio, L., Landolfi, A., Frati, G. and Lembo, G. (2008): Resistin impairs insulin-evoked vasodilation. Diab., 57:577-583. |
[121] | Benomar, Y., Gertler, A., De Lacy, P., Crépin, D., Ould Hamouda, H., Riffault, L. and Taouis, M. (2013): Central Resistin Overexposure Induces Insulin Resistance Through Toll-Like Receptor 4. Diabetes, 62 (1): 102-114. |
[122] | Li, Y., Wang, Y., Li, Q., Chen, Y., Sun, S.Z., Zhang, W.D. and Jia, Q. (2007): Effect of resistin on vascular endothelium secretion dysfunction in rats. Endothelium, 14:207-14. |
[123] | Qi, Q., Wang, J., Li, H., Yu, Z., Ye, X., Hu, F.B., Franco, O.H., Pan, A., Liu, Y., Lin, X. (2008): Association of resistin with inflammatory and fibrinolytic markers, insulin resistance, and metabolic syndrome in middle-aged and older Chinese. Eur. J. Endocrinol., 159:585-93. |
[124] | Lundgren, C., Brown, S., Nordt, T., Sobel, B., Fujii, S. (1996): Elaborationof type-1 plasminogen activator inhibitor from adipocytes. Circulation, 93:106-110. |
[125] | Morgana, N.E. and Edrees, M.H. (2013): A Possible Role for Chemerin; a Novel Adipokine in the Haemostatic and Atherogenic Disorders Related to Obesity in White Albino Rats. The Open Obesity Journal, 5: 65-71. |
[126] | Landgraf, K., Friebe, D., Ullrich, T., Kratzsch, J., Dittrich, K. Herberth, G. Adams, V., Kiess, W., Erbs, S., Körner, A. (2012): Chemerin as a Mediator between Obesity and Vascular Inflammation in Children. Clin. Endocrinol. Metab., 97 (4): E556-64. |
[127] | Yan, Q., Zhang, Y., Hong, J., Gu, W., Dai, M., Shi, J., Zhai, Y., Wang, W., Li, XLi, X. and Ning, G. (2012): The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine; 41(2):281-8. |